Analysts Set Aktis Oncology (NASDAQ:AKTS) Target Price at $35.00

Shares of Aktis Oncology (NASDAQ:AKTS) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $35.00.

A number of analysts have recently issued reports on the company. HC Wainwright boosted their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Raymond James Financial began coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price target on the stock. Wedbush began coverage on shares of Aktis Oncology in a research note on Wednesday, August 19th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $27.05 on Monday. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19. The stock has a market capitalization of $1.45 billion and a P/E ratio of -32.99. The business’s fifty day moving average price is $25.64 and its 200 day moving average price is $21.82.

Aktis Oncology (NASDAQ:AKTS) last posted its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $2.70 million. As a group, sell-side analysts predict that Aktis Oncology will post -1.8 EPS for the current year.

Insider Buying and Selling at Aktis Oncology

In related news, Director Ken Herrmann sold 4,856 shares of Aktis Oncology stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at approximately $86,107.36. The trade was a 58.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new position in shares of Aktis Oncology during the second quarter worth about $32,000. AXQ Capital LP acquired a new stake in shares of Aktis Oncology in the second quarter valued at about $226,000. Susquehanna International Group LLP purchased a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $278,000. California State Teachers Retirement System purchased a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $288,000. Finally, Deutsche Bank AG lifted its position in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after acquiring an additional 6,942 shares in the last quarter. 28.84% of the stock is owned by hedge funds and other institutional investors.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.